Geode Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,297,582
| Closed | -$6.99M | – | 4548 |
|
|
2024
Q4 | $6.99M | Buy |
2,297,582
+7,928
| +0.3% | +$34.5K | ﹤0.01% | 2566 |
|
|
2024
Q3 | $11.9M | Sell |
2,289,654
-8,311
| -0.4% | -$41.3K | ﹤0.01% | 2276 |
|
|
2024
Q2 | $5.91M | Buy |
2,297,965
+327,127
| +17% | +$1.12M | ﹤0.01% | 2632 |
|
|
2024
Q1 | $9.7M | Buy |
1,970,838
+46,417
| +2% | +$275K | ﹤0.01% | 2341 |
|
|
2023
Q4 | $16.9M | Buy |
1,924,421
+144,144
| +8% | +$1.18M | ﹤0.01% | 2015 |
|
|
2023
Q3 | $20.4M | Buy |
1,780,277
+84,767
| +5% | +$1.63M | ﹤0.01% | 1806 |
|
|
2023
Q2 | $42.9M | Buy |
1,695,510
+98,996
| +6% | +$3.08M | 0.01% | 1352 |
|
|
2023
Q1 | $51.4M | Buy |
1,596,514
+62,069
| +4% | +$1.93M | 0.01% | 1162 |
|
|
2022
Q4 | $28.3M | Buy |
1,534,445
+151,204
| +11% | +$3.46M | ﹤0.01% | 1537 |
|
|
2022
Q3 | $37.3M | Buy |
1,383,241
+146,289
| +12% | +$2.97M | 0.01% | 1296 |
|
|
2022
Q2 | $17.1M | Sell |
1,236,952
-99,239
| -7% | -$1.53M | ﹤0.01% | 1868 |
|
|
2022
Q1 | $26.1M | Buy |
1,336,191
+24,111
| +2% | +$366K | ﹤0.01% | 1703 |
|
|
2021
Q4 | $21.4M | Buy |
1,312,080
+107,692
| +9% | +$1.8M | ﹤0.01% | 1918 |
|
|
2021
Q3 | $33.6M | Buy |
1,204,388
+577
| +0% | +$16.5K | ﹤0.01% | 1607 |
|
|
2021
Q2 | $35.7M | Buy |
1,203,811
+83,303
| +7% | +$2.4M | ﹤0.01% | 1584 |
|
|
2021
Q1 | $31.3M | Buy |
1,120,508
+128,414
| +13% | +$3.55M | ﹤0.01% | 1575 |
|
|
2020
Q4 | $28.1M | Buy |
992,094
+51,418
| +5% | +$1.33M | ﹤0.01% | 1504 |
|
|
2020
Q3 | $23.6M | Buy |
940,676
+143,224
| +18% | +$3.76M | ﹤0.01% | 1408 |
|
|
2020
Q2 | $19.5M | Buy |
797,452
+73,582
| +10% | +$1.45M | ﹤0.01% | 1531 |
|
|
2020
Q1 | $10.7M | Buy |
723,870
+136,718
| +23% | +$2.83M | ﹤0.01% | 1701 |
|
|
2019
Q4 | $9.53M | Buy |
587,152
+9,896
| +2% | +$153K | ﹤0.01% | 2048 |
|
|
2019
Q3 | $7.5M | Buy |
577,256
+16,142
| +3% | +$197K | ﹤0.01% | 2123 |
|
|
2019
Q2 | $7.28M | Buy |
561,114
+72,767
| +15% | +$917K | ﹤0.01% | 2151 |
|
|
2019
Q1 | $7.7M | Buy |
488,347
+102,529
| +27% | +$1.78M | ﹤0.01% | 2069 |
|
|
2018
Q4 | $7.77M | Buy |
385,818
+48,325
| +14% | +$1.06M | ﹤0.01% | 1950 |
|
|
2018
Q3 | $8.39M | Buy |
337,493
+33,404
| +11% | +$908K | ﹤0.01% | 2047 |
|
|
2018
Q2 | $8.35M | Buy |
304,089
+41,697
| +16% | +$1.25M | ﹤0.01% | 2014 |
|
|
2018
Q1 | $8.08M | Buy |
262,392
+42,831
| +20% | +$1.38M | ﹤0.01% | 1913 |
|
|
2017
Q4 | $7.85M | Buy |
219,561
+16,541
| +8% | +$475K | ﹤0.01% | 1913 |
|
|
2017
Q3 | $5.59M | Buy |
203,020
+11,129
| +6% | +$270K | ﹤0.01% | 2132 |
|
|
2017
Q2 | $5.07M | Buy |
191,891
+13,456
| +8% | +$300K | ﹤0.01% | 2138 |
|
|
2017
Q1 | $3.71M | Buy |
178,435
+25,075
| +16% | +$515K | ﹤0.01% | 2285 |
|
|
2016
Q4 | $3.17M | Buy |
153,360
+5,247
| +4% | +$87.9K | ﹤0.01% | 2351 |
|
|
2016
Q3 | $2.4M | Buy |
148,113
+4,656
| +3% | +$67.6K | ﹤0.01% | 2443 |
|
|
2016
Q2 | $1.95M | Buy |
143,457
+3,417
| +2% | +$60.4K | ﹤0.01% | 2502 |
|
|
2016
Q1 | $2.44K | Buy |
140,040
+11,322
| +9% | +$230K | ﹤0.01% | 2332 |
|
|
2015
Q4 | $4.4M | Buy |
128,718
+31,815
| +33% | +$1.1M | ﹤0.01% | 1957 |
|
|
2015
Q3 | $2.88M | Buy |
96,903
+19,680
| +25% | +$598K | ﹤0.01% | 2198 |
|
|
2015
Q2 | $2.47M | Buy |
77,223
+6,451
| +9% | +$166K | ﹤0.01% | 2363 |
|
|
2015
Q1 | $1.47M | Buy |
70,772
+5,868
| +9% | +$101K | ﹤0.01% | 2637 |
|
|
2014
Q4 | $1.1M | Buy |
64,904
+1,773
| +3% | +$31K | ﹤0.01% | 2782 |
|
|
2014
Q3 | $1.22M | Buy |
63,131
+22,182
| +54% | +$578K | ﹤0.01% | 2665 |
|
|
2014
Q2 | $1.39M | Buy |
40,949
+5,806
| +17% | +$182K | ﹤0.01% | 2600 |
|
|
2014
Q1 | $1.11M | Buy |
+35,143
| New | +$1.1M | ﹤0.01% | 2728 |
|
Other funds holding RVNC
Geode Capital Management's RVNC Position: Q1 2025 in Review
Geode Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,297,582 shares — an estimated $6.99M sold.
Geode Capital Management first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $51.4M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Geode Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Geode Capital Management sold 2,297,582 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $6.99M.
- Geode Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Geode Capital Management's Revance Therapeutics, Inc. position peaked at $51.4M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.